Dr. Novack will be giving several presentations at the Annual Meeting of the American Academy of Ophthalmology in New Orleans in November 2017. On 9 November, he will lead a breakfast with FDA at the OIS AAO. On 11 November, he will give a talk at the Glaucoma Sub-specialty day on New Molecules in Glaucoma Development. On 14 November, he will give a talk on “An update on newly FDA-approved drugs and new drugs in clinical trials” at the Prevent Blindness America symposium. Finally, he will be part of a course on “Empowering glaucoma patients to take better care of themselves.”
Dr. Novack is giving a number of presentations at the upcoming American Academy of Ophthalmology annual meeting in New Orleans. On 9 November, he will chair a breakfast session at [email protected]. On 11 November, he will be presenting “New Molecules in Clinical Development” at the Glaucoma sub-specialty day. On 14 November, he will be presenting a talk on “Newly FDA-approved drugs and new drugs in clinical trials” in a glaucoma meeting sponsored by Prevent Blindness America. Also on 14 November, he will be part of a group of distinguished faculty teaching a course on “Empowering glaucoma patients to take better care of themselves”.
Several groups have declared July 2017 as Dry Eye Awareness Month.
TFOS DEWS II™ highlights will be presented at a July 12 Congressional Briefing entitled Dry Eye: An Updated Definition, A Greater Impact on Vision Health—co-hosted by TFOS and the Alliance for Eye and Vision Research (AEVR)—to be held from 12 Noon – 1:15 pm in Rayburn 2168 (Gold Room). The Briefing will be bookended by a “Test Your Tears” Dry Eye Screening and Dry Eye Researcher Poster Presentation from 11:30 am – 2 pm. The vision community is making Congressional education about dry eye a priority since it impacts healthcare policy, as it is one of the most frequent causes of patient visits to eye care providers, and since federal research funding from the National Institutes of Health (NIH), including its National Eye Institute (NEI), is being used to study dry eye causes and develop treatments.
Also, stay tuned for the TFOS DEWS II report, due 1 July 2017 in The Ocular Surface.
Dr. Novack attended the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, MD. This was his approximately 33rd ARVO meeting. He presented in the Special Interest Group on the TFOS Dry Eye Workshop II. As well he had two side-by-side posters in a glaucoma poster session- one on an investigational drug, and the other on a recently cleared minimally-invasive glaucoma stent (MIGS). He was also an author on a oral presentation of an investigational drug to treat elevated intraocular pressure.
Dr. Novack in front of his two, side-by-side, posters on glaucoma therapies
TFOS DEWS II Chairs (Dr. Novack is 5th from left)
Dr. Novack gave a talk on the preclinical needs for development of ophthalmic products at the Spring meeting of the Boston Area Pharmacology Toxicology Group (BAPTG). The meeting was hosted by Biogen at their facility in Cambridge, MA.
Dr. Novack, a 30+ year member of the American Society of Clinical Pharmacology and Therapeutics, attended the annual meeting in Washington DC in March 2017. He participated in several trainee events, including a trainee luncheon (pictured below) and a “speed mentoring” event. He was a co-founder of the latter for this society.